

**BIOCON GROUP**

**FACT SHEET**

**June - 2025**

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 26	Q1 FY 25	Variance %
<b>INCOME</b>			
Generics	697	659	6%
Biosimilars	2,458	2,083	18%
CRDMO*	875	790	11%
Inter-segment	(87)	(100)	-13%
<b>Revenue from operations #</b>	<b>3,942</b>	<b>3,433</b>	<b>15%</b>
Other income	80	1,134	-93%
<b>TOTAL REVENUE</b>	<b>4,022</b>	<b>4,567</b>	<b>-12%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,514	1,276	19%
Staff costs	783	702	12%
Research & Development expenses**	205	228	-10%
Other expenses	692	606	14%
<b>Manufacturing, staff &amp; other expenses</b>	<b>3,193</b>	<b>2,812</b>	<b>14%</b>
<b>EBITDA</b>	<b>829</b>	<b>1,755</b>	<b>-53%</b>
Interest & Finance charges	277	236	17%
Depreciation & Amortisation	455	405	12%
<b>PBT</b>	<b>97</b>	<b>1,114</b>	<b>-91%</b>
Exceptional item	-	32	-100%
<b>PBT</b>	<b>97</b>	<b>1,146</b>	<b>-92%</b>
Taxes	8	273	-97%
Taxes on exceptional item	-	11	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>89</b>	<b>862</b>	<b>-90%</b>
Minority interest	58	193	-70%
Minority interest on exceptional item	-	10	0%
<b>NET PROFIT FOR THE PERIOD</b>	<b>31</b>	<b>660</b>	<b>-95%</b>
<b>EPS Rs.</b>	<b>0.3</b>	<b>5.5</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>	<b>31</b>	<b>648</b>	<b>-95%</b>
Exceptional item, net of taxes	-	12	0%
<b>NET PROFIT FOR THE PERIOD</b>	<b>31</b>	<b>660</b>	<b>-95%</b>
# Licensing Income	4	6	
* Earlier Research Services			
** Gross Research & Development expenses	205	228	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 26	Q4 FY 25	Variance %
<b>INCOME</b>			
Generics	697	1,048	-34%
Biosimilars	2,458	2,463	0%
CRDMO*	875	1,018	-14%
Inter-segment	(87)	(112)	-22%
<b>Revenue from operations #</b>	<b>3,942</b>	<b>4,417</b>	<b>-11%</b>
Other income	80	37	116%
<b>TOTAL REVENUE</b>	<b>4,022</b>	<b>4,454</b>	<b>-10%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,514	1,567	-3%
Staff costs	783	765	2%
Research & Development expenses**	205	231	-11%
Other expenses	692	776	-11%
<b>Manufacturing, staff &amp; other expenses</b>	<b>3,193</b>	<b>3,339</b>	<b>-4%</b>
<b>EBITDA</b>	<b>829</b>	<b>1,115</b>	<b>-26%</b>
Interest & Finance charges	277	212	30%
Depreciation & Amortisation	455	436	4%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>97</b>	<b>466</b>	<b>-79%</b>
Exceptional item, Net	-	21	-100%
<b>PBT</b>	<b>97</b>	<b>487</b>	<b>-80%</b>
Taxes	8	24	-68%
Taxes on exceptional item	-	4	-100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>89</b>	<b>459</b>	<b>-81%</b>
Minority interest	58	109	-47%
Minority interest on exceptional item	-	6	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>31</b>	<b>344</b>	<b>-91%</b>
<b>EPS Rs.</b>	<b>0.3</b>	<b>2.9</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>	<b>31</b>	<b>333</b>	<b>-91%</b>
Exceptional item	-	11	
<b>NET PROFIT FOR THE PERIOD</b>	<b>31</b>	<b>344</b>	<b>-91%</b>
# Licensing Income	4	8	
* Earlier Research Services			
** Gross Research & Development expenses	205	231	

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Crores)

Particulars	Jun 30, 2025	Mar 31, 2025
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	8,879	8,708
(b) Capital work-in-progress	4,156	4,102
(c) Right-of-use assets	594	604
(d) Goodwill	16,839	16,786
(e) Other intangible assets	5,733	5,865
(f) Intangible assets under development	4,421	4,407
(g) Financial assets		
Investments	502	680
Derivative assets	190	187
Other financial assets	88	68
(h) Income tax asset, net	405	371
(i) Deferred tax asset, net	222	258
(j) Other non-current assets	397	476
<b>Non-current assets</b>	<b>42,426</b>	<b>42,512</b>
<b>Current assets</b>		
(a) Inventories	5,756	4,931
(b) Financial assets		
Investments	3,184	447
Trade receivables	5,845	5,488
Cash and cash equivalents	2,337	3,227
Other bank balances	568	893
Derivative assets	99	96
Other financial assets	348	456
(c) Other current assets	832	747
<b>Current assets</b>	<b>18,969</b>	<b>16,285</b>
<b>TOTAL - ASSETS</b>	<b>61,395</b>	<b>58,797</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	669	600
(b) Other equity	25,200	21,044
<b>Equity attributable to owners of the Company</b>	<b>25,869</b>	<b>21,644</b>
Non-controlling interests	6,129	6,069
<b>Total Equity</b>	<b>31,998</b>	<b>27,713</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	10,076	12,405
Lease liabilities	537	539
Derivative liabilities	63	23
Other financial liabilities	1,379	2,828
(b) Other non-current liabilities	332	336
(c) Provisions	236	261
(d) Deferred tax liability, net	225	358
<b>Non-current liabilities</b>	<b>12,848</b>	<b>16,750</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	5,753	5,350
Lease liabilities	67	67
Trade payables	6,941	6,549
Derivative liabilities	156	46
Other financial liabilities	2,247	933
(b) Other current liabilities	953	1,024
(c) Provisions	190	192
(d) Income tax liability, net	242	173
<b>Current liabilities</b>	<b>16,549</b>	<b>14,334</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>61,395</b>	<b>58,797</b>